Market Overview:
The global pegfilgrastim market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for biosimilars, and growing number of approvals for pegfilgrastim products. Based on type, the global pegfilgrastim market is segmented into pegfilgrastim and biosimilar pegfilgrastim. The biosimilar segment is expected to grow at a higher CAGR than the other segment during the forecast period. This growth can be attributed to factors such as increasing demand for cheaper alternatives and rising preference for biosimilars over branded drugs. Based on application, the global Pegfilgastrim market is divided into hospital and drug store segments. Region-wise, North America accounts for majority share in terms revenue generated by Global PegFilgastrim Market followed by Europe & Asia Pacific respectively .
Product Definition:
Pegfilgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog. Pegfilgrastim is produced by genetically engineered Escherichia coli cells and purified by column chromatography. It consists of the human G-CSF sequence with an N‑terminal polyethylene glycol (PEG) moiety covalently attached to the protein. The PEGylated form of filgrastim has a longer half-life and greater potency than native filgrastim, allowing for once monthly administration.
Pegfilgrastim:
Pegfilgrastim is a type of filgrastim which is manufactured by the Sino-American Pharmaceutical Company (SAPPH) and distributed in the U.S. and Europe by Roche as pegfilgrastim biosimilar or peginterferon 26 Feasible Solution (PFS).
Pegfilgrastim Biosimilar:
Pegfilgrastim is biosimilar of Filgrastim. It is a type of long-acting (glucagon-like) growth hormone secretagogue, which was developed by Eli Lilly and Company and distributed by them as Elelyso until 2016.
Application Insights:
Based on the application, the market is segmented into hospital and drug store Pegfilgrastim. Hospital was estimated as the largest revenue generating segment in 2017 owing to increasing number of patients suffering from cancer and other life-threatening diseases at a global level. The growing healthcare sector at global level can be attributed for this growth factor. According to WHO, it has been estimated that by 2030, nearly 90% of all deaths would occur in low- & middle-income countries due to chronic diseases such as cancer and cardiovascular disorders which are preventable with effective treatment options such as pegfilgrastim. Thus, rising incidences of fatal diseases coupled with high unmet needs will drive demand over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some factors responsible for its growth. In addition, growing number of FDA approved pegfilgrastim products is expected to drive the region’s growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to huge unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China and India.
In November 2016; Novo Nordisk announced that it received approval for Pataday (pegfilgrastim-xl) from Chinese government which was later commercialized in April 2017 under brand name Neupogen (Filgrastim-snd).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the pegfilgrastim market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for pegfilgrastim products over the forecast period.
- Rising geriatric population: The global geriatric population is increasing at a rapid pace and this is expected to drive demand for pegfilgrastim products over the forecast period as elderly patients are more susceptible to developing infections and require prophylactic treatment with G-CSFs such as pegfilgrastim prior to chemotherapy or radiotherapy treatment sessions.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pegfilgrastim Market Research Report
By Type
Pegfilgrastim, Pegfilgrastim Biosimilar
By Application
Hospital, Drug store
By Companies
Amgen, Mylan, Coherus BioSciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
181
Number of Tables & Figures
127
Customization Available
Yes, the report can be customized as per your need.
Global Pegfilgrastim Market Report Segments:
The global Pegfilgrastim market is segmented on the basis of:
Types
Pegfilgrastim, Pegfilgrastim Biosimilar
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drug store
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Mylan
- Coherus BioSciences
Highlights of The Pegfilgrastim Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Pegfilgrastim
- Pegfilgrastim Biosimilar
- By Application:
- Hospital
- Drug store
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pegfilgrastim Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pegfilgrastim is a type of medication used to help increase the number of white blood cells in the body. This can help reduce the risk of infection.
Some of the major companies in the pegfilgrastim market are Amgen, Mylan, Coherus BioSciences.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pegfilgrastim Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Pegfilgrastim Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Pegfilgrastim Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Pegfilgrastim Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Pegfilgrastim Market Size & Forecast, 2020-2028 4.5.1 Pegfilgrastim Market Size and Y-o-Y Growth 4.5.2 Pegfilgrastim Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Pegfilgrastim
5.2.2 Pegfilgrastim Biosimilar
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drug store
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pegfilgrastim Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pegfilgrastim Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Pegfilgrastim
9.6.2 Pegfilgrastim Biosimilar
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drug store
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Pegfilgrastim
10.6.2 Pegfilgrastim Biosimilar
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drug store
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Pegfilgrastim
11.6.2 Pegfilgrastim Biosimilar
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drug store
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Pegfilgrastim
12.6.2 Pegfilgrastim Biosimilar
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drug store
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Pegfilgrastim
13.6.2 Pegfilgrastim Biosimilar
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drug store
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pegfilgrastim Market: Competitive Dashboard
14.2 Global Pegfilgrastim Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Mylan
14.3.3 Coherus BioSciences